Filtered By:
Condition: Hemorrhagic Stroke
Management: Healthcare Costs

This page shows you your search results in order of relevance.

Order by Relevance | Date

Total 18 results found since Jan 2013.

Trimming the fat in acute ischemic stroke: an assessment of 24‐h CT scans in tPA patients
ConclusionsOur results demonstrate that routine 24‐h computed tomography scan in patients without 24‐h National Institute of Health Stroke Scale worsening (especially those with baseline National Institute of Health Stroke Scale ≤10) is less likely to yield information that results in a deviation from standard acute stroke care. No patient without worsening and baseline National Institute of Health Stroke Scale ≤10 had parenchymal hematoma on 24‐h computed tomography. Application of the National Institute of Health Stroke Scale to distinguish patients who should have 24‐h follow‐up imaging from those who will...
Source: International Journal of Stroke - June 3, 2014 Category: Neurology Authors: Alexander J. George, Amelia K. Boehme, Casey R. Dunn, T. Beasley, James E. Siegler, Karen C. Albright, Ramy El Khoury, Sheryl Martin‐Schild Tags: Research Source Type: research

Impact of Atrial Fibrillation on Stroke-Related Healthcare Costs Stroke
Conclusion Stroke-related care for IS, HS, and TIA is costly, especially among individuals with AF. Reducing the risk of AF-related stroke is important from both clinical and economic standpoints.
Source: JAHA:Journal of the American Heart Association - November 25, 2013 Category: Cardiology Authors: Sussman, M., Menzin, J., Lin, I., Kwong, W. J., Munsell, M., Friedman, M., Selim, M. Tags: Stroke Source Type: research

Abstract 301: Healthcare Costs Following Stroke and Major Bleeding Events in Nonvalvular Atrial Fibrillation Patients Session Title: Poster Session III
Conclusions: NVAF patients who have a stroke or MB event incur higher healthcare costs relative to patients without events. Interventions preventing stroke or MB events have the potential to reduce the healthcare burden associated NVAF.
Source: Circulation: Cardiovascular Quality and Outcomes - April 29, 2015 Category: Cardiology Authors: Naccarelli, G., Stokes, M., DeLeon, A., Tate, N., Wang, R., Wang, A., Fredell, J. Tags: Session Title: Poster Session III Source Type: research

Selective serotonin reuptake inhibitors (SSRIs) for stroke recovery.
CONCLUSIONS SSRIs appeared to improve dependence, disability, neurological impairment, anxiety and depression after stroke, but there was heterogeneity between trials and methodological limitations in a substantial proportion of the trials. Large, well-designed trials are now needed to determine whether SSRIs should be given routinely to patients with stroke. PMID: 23903272 [PubMed - in process]
Source: Sao Paulo Medical Journal - August 3, 2013 Category: Journals (General) Authors: Mead GE, Hsieh CF, Lee R, Kutlubaev MA, Claxton A, Hankey GJ, Hacklett ML Tags: Sao Paulo Med J Source Type: research

MedyMatch looks to future of stroke detection with AI platform launch
Artificial intelligence healthcare startup MedyMatch Technology said late last month its AI platform designed to detect intracranial hemorrhage or brain bleeds is now available for research. The development is a milestone for the company, but is only the 1st stop for the platform, CEO Gene Saragnese told MassDevice.com in an interview. “What we’ve done at MedyMatch is develop not just an algorithm, but an AI platform which looks at the entire patient – that is to say, the full richness of 3D imaging plus other patient attributes – to allow us, firstly, to understand whether that person is hemorrhagic st...
Source: Mass Device - December 5, 2016 Category: Medical Equipment Authors: Fink Densford Tags: Imaging Software / IT MedyMatch Source Type: news

CERENOVUS Launches New Suite of Technologies to Advance Stroke Treatment
IRVINE, CA – September 9, 2020 – CERENOVUS, part of Johnson & Johnson Medical Devices Companies* today announced that it has launched CERENOVUS Stroke Solutions™, which includes a suite of three devices designed to aid physicians in clot removal procedures. The announcement was made during the virtual European Society of Minimally Invasive Neurological Therapy (ESMINT).Strokes are the second leading cause of death globally, and account for an estimated 140,000 deaths in the United States each year.[i],[ii] Over half of stroke survivors become chronically disabled placing an estimated $34 billion economic burden o...
Source: Johnson and Johnson - September 9, 2020 Category: Pharmaceuticals Source Type: news

Impact of Atrial Fibrillation on Stroke-Related Healthcare Costs Hypertension
Conclusion Stroke-related care for IS, HS, and TIA is costly, especially among individuals with AF. Reducing the risk of AF-related stroke is important from both clinical and economic standpoints.
Source: JAHA:Journal of the American Heart Association - November 25, 2013 Category: Cardiology Authors: Sussman, M., Menzin, J., Lin, I., Kwong, W. J., Munsell, M., Friedman, M., Selim, M. Tags: Hypertension Source Type: research

Economic impact of patients admitted to stroke units in Spain
Conclusions The cost of patients admitted to stroke units in Spain is €27,711 per patient/year. More than two-thirds are social costs, mainly informal care. Stroke remains a major burden on health systems and society, so additional efforts are needed for its prevention.
Source: The European Journal of Health Economics - April 14, 2016 Category: Health Management Source Type: research

'Not enough over-50s' taking aspirin to prevent heart disease
Conclusion This study doesn't really tell us anything we didn't already know. Aspirin has been used for many years to prevent heart attacks and strokes in people with cardiovascular disease. Aspirin's wider use is controversial, because of the potential side effects. What this study does add is an estimate of what might happen if all people in the US who were advised to take aspirin under US guidelines, actually did so. (The researchers say that 40% of men and 10% of women advised to take aspirin don't take it). The study assumes that people would get the same benefits as those seen in clinical trials of aspirin. This is u...
Source: NHS News Feed - December 1, 2016 Category: Consumer Health News Tags: Heart/lungs Medication Older people Source Type: news

Outcomes in atrial fibrillation patients on combined warfarin & antiarrhythmic therapy
Conclusions: Allowing for differences in prescribing practice, AF/AFL patients treated with W+A are at higher risk of stroke and arterial embolism, and have higher healthcare use and costs, than patients receiving W+OAAD.
Source: International Journal of Cardiology - February 15, 2012 Category: Cardiology Authors: Annie Guérin, Jay Lin, Mehul Jhaveri, Eric Q. Wu, Andrew P. Yu, Martin Cloutier, Genevieve Gauthier, Joseph S. Alpert Tags: Original Articles Source Type: research

Abstract 250: Economic Burden of Mortality and Cardiovascular Events among Patients with Acute Coronary Syndromes in a Commercial Health Plan Poster Session III
Conclusion: Our findings suggest that a modest 10% increase in anticoagulant use among patients with ACS would reduce mortality, MI, ST and related healthcare costs by 4%, 0.7%, and 3%, respectively. Addition of anticoagulation therapy potentially reduces the incidence of ACS-related mortality, MI, ST and associated healthcare costs to a commercial health plan, and benefits from anticoagulation use should be balanced against the risk of bleeding.
Source: Circulation: Cardiovascular Quality and Outcomes - May 15, 2013 Category: Cardiology Authors: Ogden, K., Patel, A. A., Mody, S. H., Veerman, M., Crivera, C., Quock, T. P. Tags: Poster Session III Source Type: research

Preventable Cases of Oral Anticoagulant-Induced Bleeding: Data From the Spontaneous Reporting System
Conclusion: Our findings describe the most reported risk factors for preventability of oral anticoagulant-induced bleedings. These factors may be useful for targeting interventions to improve pharmacovigilance activities in our regional territory and to reduce the burden of medication errors and inappropriate prescription. Introduction Oral anticoagulant therapy is widely used for the prevention of stroke and systemic embolism in patients with atrial fibrillation, or for the prevention and treatment of deep vein thrombosis and pulmonary embolism (Raj et al., 1994; Monaco et al., 2017). Oral anticoagulants can be di...
Source: Frontiers in Pharmacology - April 29, 2019 Category: Drugs & Pharmacology Source Type: research

Cost-effectiveness of non-vitamin K antagonist oral anticoagulants for atrial fibrillation in Portugal
Conclusions Apixaban is a cost-effective alternative to warfarin and dabigatran and is dominant over rivaroxaban in AF patients from the perspective of the Portuguese national healthcare system. These conclusions are based on indirect comparisons, but despite this limitation, the information is useful for healthcare decision-makers.
Source: Revista Portuguesa de Cardiologia - January 12, 2016 Category: Cardiology Source Type: research

Abstract 150: Machine Learning Methodology Predicts Comorbidities are Associated With Increased Total Healthcare Costs Among Patients With Severe Peripheral Artery Disease Session Title: Poster Session II
Conclusion: In this study, the presence of chronic ulcers in the lower extremities and CKD were two factors most predictive of increased all-cause total HC in a geographically diverse population of severe PAD patients.
Source: Circulation: Cardiovascular Quality and Outcomes - March 31, 2017 Category: Cardiology Authors: Berger, J. S., Haskell, L., Ting, W., Lurie, F., Eapen, Z., Valko, M., Alas, V., Rich, K., Crivera, C., Schein, J. Tags: Session Title: Poster Session II Source Type: research

Clinical Outcomes of Acute Myocardial Infarction Hospitalizations with Systemic Lupus Erythematosus: An Analysis of Nationwide Readmissions Database
CONCLUSION: Patients with AMI and SLE had higher inpatient mortality during the index hospitalization and higher 30-day hospital readmissions compared to AMI patients without SLE. There were no significant differences in most of the other major inpatient outcomes between the two cohorts.PMID:34936910 | DOI:10.1016/j.cpcardiol.2021.101086
Source: Atherosclerosis - December 22, 2021 Category: Cardiology Authors: Shazib Sagheer Pallav Deka Dola Pathak Umair Khan Syeda Humna Zaidi Anum Akhlaq James Blankenship Ann Annis Source Type: research